| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041239490 |
| P356 | DOI | 10.1038/NPP.1993.19 |
| P698 | PubMed publication ID | 8471129 |
| P5875 | ResearchGate publication ID | 260204729 |
| P2093 | author name string | L Hermle | |
| D Borchardt | |||
| E Gouzoulis | |||
| K A Kovar | |||
| M Spitzer | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 171-176 | |
| P577 | publication date | 1993-02-01 | |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? | |
| P478 | volume | 8 |
| Q33540473 | 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. |
| Q35105559 | Acute Psychological and Neurophysiological Effects of MDMA in Humans |
| Q35095703 | Altered states: the clinical effects of Ecstasy. |
| Q40602429 | Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. |
| Q30473430 | Brain mechanisms of hallucinogens and entactogens |
| Q35839390 | Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse. |
| Q28243881 | Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices |
| Q34300503 | Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine |
| Q74790681 | Detection of designer drugs in human hair by ion mobility spectrometry (IMS) |
| Q35965775 | Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats |
| Q36960553 | Drug interactions involving ethanol and alcoholic beverages |
| Q28483370 | Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study |
| Q44136657 | Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') isomers in rat brain and blood |
| Q30428506 | Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users |
| Q74611979 | High sensitivity simultaneous determination in hair of the major constituents of ecstasy (3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyamphetamine and 3,4-methylene-dioxyethylamphetamine) by high-performance liquid chromatography with direct |
| Q73064891 | High-performance thin-layer chromatographic determination of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in urine and comparison with high-performance liquid chromatography |
| Q34528465 | Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research |
| Q73755207 | Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs |
| Q43842107 | Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. |
| Q34632991 | Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users |
| Q56961628 | MDMA |
| Q37149027 | MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology |
| Q35946697 | MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves |
| Q47369247 | Online sample concentration and analysis of drugs of abuse in human urine by micelle to solvent stacking in capillary zone electrophoresis |
| Q40126464 | Substitutional potential of mephedrone: an analysis of the subjective effects |
| Q36274846 | The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine |
| Q30341737 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). |
| Q40359394 | The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy |
| Q51889564 | [Options, limits and ethics of pharmacological neuroenhancement]. |
Search more.